Regulatory Monitoring for Healthcare in Latin America

Latin America's pharmaceutical and medical device markets are governed by some of the region's most active regulators. Brazil's ANVISA alone processes over 10,000 product registrations annually and publishes hundreds of resolutions, technical notes, and guidance documents each year. Mexico's COFEPRIS underwent a major restructuring in 2020 and has since accelerated its output of sanitary registrations and GMP requirements. For companies selling drugs, devices, or health technologies across LATAM, every market has its own registration pathway, labeling rules, and post-market surveillance obligations — and they rarely align.

Key Regulatory Bodies

• Agência Nacional de Vigilância Sanitária (ANVISA) — Brazil — One of the most comprehensive health regulators in the developing world. Oversees drug registration, medical devices, clinical trials, GMP inspections, and health product advertising. ANVISA's decisions carry significant influence across Portuguese-speaking Africa and other LATAM markets.
• Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) — Mexico — Mexico's health products regulator, responsible for drug approvals, medical device registration, sanitary permits, and advertising authorization. Restructured under the 2020 health reform, COFEPRIS has been working to reduce approval backlogs while strengthening pharmacovigilance requirements.
• Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) — Colombia — Regulates pharmaceuticals, medical devices, biologics, and food safety. INVIMA administers Colombia's sanitary registration system and has expanded its focus on biosimilar approvals and clinical trial oversight.
• Instituto de Salud Pública (ISP) — Chile — Chile's public health institute handles drug and device registration, quality control laboratory testing, and pharmacovigilance. Known for relatively efficient approval timelines compared to regional peers.
• Dirección General de Medicamentos, Insumos y Drogas (DIGEMID) — Peru — Oversees pharmaceutical registration, pricing controls, and import permits for medicines and medical devices entering the Peruvian market.

Critical Regulations

• Brazil RDC 751/2022 (Medical Device Registration) — ANVISA's updated framework for medical device and in-vitro diagnostic registration, replacing the prior RDC 185/2001. Introduced risk-based classification aligned more closely with international standards and new requirements for clinical evidence.
• Mexico NOM-241-SSA1-2021 (GMP for Pharmaceuticals) — Mexico's updated Good Manufacturing Practice standard for pharmaceutical establishments, harmonized with PIC/S guidelines. Requires compliance by domestic and foreign manufacturers seeking COFEPRIS market authorization.
• Colombia Decree 677/1995 (updated via Decree 817/2024) — Governs the registration and oversight of pharmaceuticals and biologics. Recent amendments streamlined the biosimilar approval pathway and updated post-market surveillance obligations.
• Pan American Health Organization (PAHO) Regulatory Convergence Initiatives — PAHO's regional harmonization efforts, including the System for Evaluation of Medicines (SEMED), facilitate reliance pathways where LATAM regulators can leverage ANVISA, COFEPRIS, or INVIMA reviews to expedite approvals.
• Brazil Law 13,709/2018 (LGPD) — Health Data Provisions — Brazil's general data protection law classifies health data as sensitive, imposing elevated consent and processing requirements on clinical research, telemedicine platforms, and health technology companies.

What You're Missing

Healthcare regulation in LATAM moves through multiple channels simultaneously. ANVISA publishes resolutions via the Diário Oficial da União — often with compliance deadlines as short as 90 days. COFEPRIS issues updated NOMs (Official Mexican Standards) that require manufacturers to revise labeling, testing, or documentation. INVIMA's regulatory sandbox for digital health devices creates new product categories with evolving compliance requirements.

The convergence initiatives through PAHO are accelerating, which means a regulatory decision in Brazil can influence timelines in Colombia, Chile, and Peru. Missing an ANVISA resolution on device classification can cascade into registration delays across the region.

How RegPulse Helps

RegPulse monitors ANVISA, COFEPRIS, INVIMA, ISP Chile, DIGEMID Peru, and PAHO for healthcare-relevant publications. Drug registration updates, GMP guideline changes, clinical trial requirements, and pharmacovigilance mandates are classified and delivered to your dashboard the day they're published — across Portuguese, Spanish, and English sources.